Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study

References

• Afshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. doi:10.1056/NEJMoa1614362
   PubMed Web of Science ®Google Scholar
• Fujioka K, Harris SR. Barriers and solutions for prescribing obesity pharmacotherapy. Endocrinol Metab Clin North Am. 2020;49(2):303–314. doi:10.1016/j.ecl.2020.02.007
   Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–2434. doi:10.1001/jama.2016.7602
   PubMed Web of Science ®Google Scholar
• Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403. doi:10.1038/s41574-018-0016-2
   PubMed Web of Science ®Google Scholar
• Lehmann EW, Torekov SS. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance? Cardiovasc Res. 2021;117(10):e120–e122. doi:10.1093/cvr/cvab249
   Web of Science ®Google Scholar
• Jph W, Rl B, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Christensen RM, Juhl CR, Torekov SS. Benefit-risk assessment of obesity drugs: focus on glucagon-like peptide-1 receptor agonists. Drug Saf. 2019;42(8):957–971. doi:10.1007/s40264-019-00812-7
   PubMed Web of Science ®Google Scholar
• Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317–332. doi:10.1111/dom.12596
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742. doi:10.1038/nrendo.2012.140
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–230. Fall-Winter. doi:10.1900/rds.2014.11.202
   PubMedGoogle Scholar
• Maciá-Martínez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AF. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39(1):29–43. doi:10.1007/s40264-015-0351-3
   PubMed Web of Science ®Google Scholar
• Liu C, Zou Y, Qian H. GLP-1R agonists for the treatment of obesity: a patent review (2015-present). Expert Opin Ther Pat. 2020;30(10):781–794. doi:10.1080/13543776.2020.1811851
   PubMed Web of Science ®Google Scholar
• Aaseth J, Ellefsen S, Alehagen U, Sundfør TM, Alexander J. Diets and drugs for weight loss and health in obesity - an update. Biomed Pharmacother. 2021;140:111789. doi:10.1016/j.biopha.2021.111789
   Web of Science ®Google Scholar
• Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38(6):2821–2839. doi:10.1007/s12325-021-01710-0
   PubMed Web of Science ®Google Scholar
• Grill HJ. A role for GLP-1 in treating hyperphagia and obesity. Endocrinology. 2020;161(8). doi:10.1210/endocr/bqaa093
   Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020;28(6):1050–1061. doi:10.1002/oby.22794
   PubMed Web of Science ®Google Scholar
• Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–1730. doi:10.1056/NEJMoa2028198
   PubMed Web of Science ®Google Scholar
• Giraudon M, Sturm S, Lambert N, et al. Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. Diabetes Obes Metab. 2017;19(4):537–544. doi:10.1111/dom.12850
   Web of Science ®Google Scholar
• Rosenstock J, Balas B, Charbonnel B, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36(3):498–504. doi:10.2337/dc12-0709
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561–1565. doi:10.2337/db10-0474
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885–R895. doi:10.1152/ajpregu.00520.2015
   PubMed Web of Science ®Google Scholar
• Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–347. doi:10.1111/dom.12824
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Knop FK, Asmar M. Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs? Scand J Gastroenterol. 2019;54(12):1448–1451. doi:10.1080/00365521.2019.1690673
   PubMed Web of Science ®Google Scholar
• Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–109. doi:10.1016/j.diabet.2019.101117
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266. doi:10.2337/dc17-0417
   PubMed Web of Science ®Google Scholar
• Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019;20(6):805–815. doi:10.1111/obr.12839
   PubMed Web of Science ®Google Scholar
• Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(5):426–433. doi:10.1111/j.1463-1326.2011.01364.x
   Web of Science ®Google Scholar
• Nauck MA, Petrie JR, Sesti G, et al. A Phase 2, Randomized, Dose-Finding Study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231–241. doi:10.2337/dc15-0165
   PubMed Web of Science ®Google Scholar
• Knudsen L, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155
   PubMed Web of Science ®Google Scholar
• Nuffer WA, Trujillo JM. Liraglutide: a new option for the treatment of obesity. Pharmacotherapy. 2015;35(10):926–934. doi:10.1002/phar.1639
   PubMed Web of Science ®Google Scholar